Eubank William B, Mankoff David A
Department of Radiology (S-113-RAD), Puget Sound VA Health Care System, Seattle, WA 98108-1597, USA.
Semin Nucl Med. 2005 Apr;35(2):84-99. doi: 10.1053/j.semnuclmed.2004.11.001.
18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used for detection, staging, and response monitoring in breast cancer patients. Although studies have proven its accuracy in detection of the primary tumor and axillary staging, its most important current clinical application is in detection and defining the extent of recurrent or metastatic breast cancer and for monitoring response to therapy. PET is complementary to conventional methods of staging in that it provides better sensitivity in detecting nodal and lytic bone metastases; however, it should not be considered a substitute for conventional staging studies, including computed tomography and bone scintigraphy. FDG uptake in the primary tumor carries prognostic information, but the underlying biochemical mechanisms responsible for enhanced glucose metabolism have not been completely elucidated. Future work using other PET tracers besides FDG will undoubtedly help our understanding of tumor biology and help tailor therapy to individual patient by improving our ability to quantify the therapeutic target, identify drug resistance factors, and measure and predict early response.
18F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）已用于乳腺癌患者的检测、分期及疗效监测。尽管研究已证实其在检测原发性肿瘤及腋窝分期方面的准确性，但其目前最重要的临床应用在于检测并确定复发性或转移性乳腺癌的范围以及监测治疗反应。PET与传统分期方法互为补充，因为它在检测淋巴结和溶骨性骨转移方面具有更高的灵敏度；然而，不应将其视为传统分期检查（包括计算机断层扫描和骨闪烁显像）的替代方法。原发性肿瘤中的FDG摄取具有预后信息，但导致葡萄糖代谢增强的潜在生化机制尚未完全阐明。未来使用除FDG之外的其他PET示踪剂开展的研究无疑将有助于我们理解肿瘤生物学，并通过提高我们量化治疗靶点、识别耐药因素以及测量和预测早期反应的能力，帮助为个体患者量身定制治疗方案。
